Biosynthesis of immunosuppressant tacrolimus: a review.

Author: Liqun JIN ¹ ; Di LU ¹ ; Minglin XING ¹ ; Xianwen WANG ¹ ; Zhiqiang LIU ¹ ; Yuguo ZHENG ¹
Author Information

1. College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, Zhejiang, China.
Publication Type:Journal Article
Keywords: Streptomyces tsukubaensis; biosynthesis; immunosuppressant drug; tacrolimus
MeSH: Tacrolimus; Immunosuppressive Agents; Fermentation; Macrolides; Anti-Bacterial Agents
From: Chinese Journal of Biotechnology 2023;39(8):3095-3110
CountryChina
Language:Chinese
Abstract: Tacrolimus (FK506) is a 23-membered macrolide with immunosuppressant activity that is widely used clinically for treating the rejection after organ transplantation. The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This review summarizes the progress made in tacrolimus biosynthesis via modification of metabolic pathways and control of fermentation process, with the hope to address the technical bottlenecks for tacrolimus biosynthesis and improve tacrolimus production by fermentation engineering and metabolic engineering.